Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Pyxis Oncology, Inc. | Director | Stock Option (Right to Buy) | 69.8K | $267K | $3.83 | Mar 12, 2024 | Direct |
Pyxis Oncology, Inc. | Director | Common Stock | 6K | $11.8K | $1.96 | Jun 7, 2024 | Direct |
Acrivon Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 32.5K | Mar 4, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PYXS | Pyxis Oncology, Inc. | Jun 7, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director |
PYXS | Pyxis Oncology, Inc. | Mar 12, 2024 | 1 | $0 | 4 | Mar 13, 2024 | Director |
PYXS | Pyxis Oncology, Inc. | Mar 12, 2024 | 0 | $0 | 3 | Mar 13, 2024 | Director |
ACRV | Acrivon Therapeutics, Inc. | Mar 4, 2024 | 1 | $0 | 4 | Mar 6, 2024 | Director |
ACRV | Acrivon Therapeutics, Inc. | Mar 4, 2024 | 0 | $0 | 3 | Mar 6, 2024 | Director |